院內感染 - 一個日益嚴重的問題
大便失禁
在感染爆發前控制困難梭狀芽孢桿菌(C. difficile)
Flexi-SealTM FMS 是一種封閉系統，設計用來盡可能減少帶有病菌的稀便/半稀便所造成的感染傳播。
已在體外試驗中證實可抑制困難梭狀芽孢桿菌(C. difficile)的傳播1 。封閉系統可幫助減少其他潛在治病細菌的感染，例如會產生超廣效β-內醯胺酶(ESBL)的細菌和耐甲氧西林金黃色葡萄球菌(MRSA)。
有助於降低併發症和醫療花費
院內感染是常見的住院併發症，死亡率和發病率都很高2 。這感染會造成住院時間增加，並增加治療和診斷的花費3,4。
- 每個病例的感染相關花費會超過13,675美元。
- 每個病患住院天數增加6天。
- 高達20%的住院病患會感染困難梭狀芽孢桿菌(C. difficile)，大幅影響住院天數。
- Jones S, Towers V, Welsby S, Wishin J, Bowler P. Clostridium difficile Containment Properties of a Fecal Management System: An In Vitro Investigation. Ostomy Wound Management, 2011;57(10):38–49.
- Geffers C, Gastmeier P. Nosocomial infections and multidrug-resistant organisms – epidemiologicaldata from KISS. DtschArzteblInt 2011; 108(6): 87-93.
- Beyersmann J, Gastmeier P, Grundmann H, Bärwolff S, Geffers C, Behnke M, Rüden H, Schumacher M. Use of multistate models to assess prolongation of intensive care unit stay due to nosocomial infection. Infect Control Hosp Epidemiol. 2006;27(5):493-499.
- Pittet D, Tarara D, Wenzel RP. Nosocomial bloodstream infection in critically ill patients. Excess length of stay, extra costs, and attributable mortality. JAMA. 1994;271(20):1598-601.
- O’Brien JA, Lahue BJ, Caro JJ, Davidson DM. The emerging infectious challenge of Clostridium difficile-associated disease in Massachusetts hospitals: clinical and economic consequences. Infect Control Hosp Epidemiol. 2007:28(11):1219-1227.
- Kyne L, Hamel MB, Polavaram R, Kelly CP. Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. CID, 2002;34:346-53.